ClinicalTrials.gg
RecruitingNCT07317934Updated Aug 6, 2026

Efficacy and Safety of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (STELLAR)

A Phase 3 interventional study of LX102 and Aflibercept in Neovascular Age-Related Macular Degeneration (nAMD) and Wet AMD, sponsored by Innostellar Biotherapeutics Co.,Ltd. Recruiting at 36 sites in China. Open to participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-08-06.

Sponsored by Innostellar Biotherapeutics Co.,Ltd · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
388
Allocation
Randomized
Ages
50 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 107 studies in Macular Degeneration with a site in China — 36 open to participants now, 43 under way, 9 of them phase 3. Macular Degeneration · China.

Planned enrollment
15th of 91
388 · median 62
Started
2026
with 8 others
Phase 3
18 of 107
4 open now
Primary completion
2028-03
later than 33 of 42 live
Registered
97th of 107
by date
Lead sponsor
3 of 107
Innostellar Biotherapeutics Co.,Ltd

Among the 107 studies in Macular Degeneration with a site in China, this one is the 15th largest by planned enrollment of the 91 interventional ones that give a count, is one of 9 that started in 2026, is one of 18 in phase 3, reaches primary completion later than 33 of the 42 other live ones, and was the 97th registered.

Macular Degeneration

1,461 studies on the registry are indexed under Macular Degeneration; 237 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

36 of the 107 studies in Macular Degeneration with a site in China are open now. Recruiting first, the newest first:

30 more — sign in →

All 36 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 167 Macular Degeneration studies recruiting now, 118 (71%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 36 take healthy volunteers.

This study: 50 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 107 studies in Macular Degeneration with a site in China, or all of them as a file.
02

Study summary

This is a Phase III, randomized, open-label, active-controlled study to evaluate the efficacy and safety of subretinal injection of LX102 in participants with neovascular age-related macular degeneration. The study will evaluate a single subretinal injection of LX102 compared to an active comparator. The primary endpoint of this study is the mean change from D0 in BCVA based on an average at weeks 48 and 56.

03

Conditions studied

  • Neovascular Age-Related Macular Degeneration (nAMD)
  • Wet AMD
04

Who can participate

Ages eligible
50 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Willing and able to provide written, signed for this study;
  2. Age ≥50 and ≤80 years old;
  3. Active CNV secondary to nAMD in the study eye confirmed by FFA or OCT;
  4. The BCVA between 24 and 78 letters (inclusive) in the study eye at Screening;
  5. Demonstrated clinical response to aflibercept treatments in the study eye confirmed by the Reading Center;
  6. No anti-VEGF therapy in study eye within 28 days before screening;
  7. Must be pseudophakic in the study eye.

Exclusion criteria

Exclusion Criteria:

  1. Any condition in the investigator's opinion that could limit VA improvement in the study eye.
  2. CNV or macular edema in the study eye secondary to any causes other than AMD
  3. Subfoveal atrophy in the study eye, as determined by CRC;
  4. History of retinal detachment in the study eye at any time;
  5. History of idiopathic or uveitis in either eye;
  6. Advanced glaucoma in the study eye;
  7. History of vitrectomy surgery in the study eye;
  8. History of intraocular surgery within 1 month before screening in the study eye;
  9. History of ocular or systemic gene therapy;
  10. Recent myocardial infarction, cerebrovascular accident, or within the past 6 months.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
388 participants (estimated)

Study arms

  • Experimental
    LX102

    Genetic: LX102

  • Active comparator
    Aflibercept

    Biological: Aflibercept

Interventions

  • GeneticLX102

    Study eyes will receive a single subretinal injection of LX102.

  • BiologicalAflibercept

    Study eyes will receive 3 monthly loading doses of aflibercetp 2mg IVT and aflibercept 2mg IVT every 8 weeks.

06

What researchers measure

Primary outcomes

  1. Mean change from D0 in BCVA based on an average at weeks 48 and 56.

    Mean change from D0 in BCVA as measured by the early treatment diabetic retinopathy study (ETDRS) visual acuity chart based on an average at weeks 48 and 56.

    Time frame: Week 56

Secondary outcomes

  1. Proportion of participants with improved BCVA

    Proportion of participants with improved BCVA at week 56 and week 104

    Time frame: Week 56 and week 104

  2. Proportion of participants with worsened BCVA

    Proportion of participants with worsened BCVA at week 56 and week 104

    Time frame: Week 56 and week 104

  3. Mean change from D0 in CST based on an average at weeks 48 and 56

    Mean change from D0 in central subfield thickness (CST) based on an average at weeks 48 and 56

    Time frame: Week 56

  4. Proportion of participants without SRF/IRF on OCT at week 56

    Proportion of participants without SRF/IRF on OCT at week 56

    Time frame: Week 56

  5. Proportion of participants who were supplemental anti-VEGF injection-free

    Proportion of participants with no supplemental anti-VEGF injection through 56 weeks

    Time frame: Through 56 weeks

  6. Proportion of participants who received 1 or 2 aflibercept injections

    Proportion of participants received ≤2 supplemental anti-VEGF injections through 56 weeks

    Time frame: Through 56 weeks

  7. Supplemental anti-VEGF injection annualized rate after LX102 administration through Week 56

    Mean annualized number of anti-VEGF injections after LX102 administration through 56 weeks.

    Time frame: Through 56 weeks

  8. Incidence of ocular and nonocular AEs and SAEs

    Incidence of Adverse events (AE) and Serious adverse events (SAE) over 56 weeks

    Time frame: 56 weeks

  9. Immunogenicity characteristics of LX102

    Immunogenicity measurements (LX102 randomized participants) ; measure description: Immunogenicity measurements (vector shedding, serum antibodies to AAV2 and serum antibodies to LX102 TP)

    Time frame: 56 weeks

07

Study locations

36 of 36 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Mar 2028, 26 months after the start.

Of 77 industry-sponsored phase 3 interventional studies under Macular Degeneration, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 33. This study's planned 26 months is close to that.

Counting every sponsor, half of 83 studies reached it within 24 months; a quarter within 20 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2025
First posted
Jan 5, 2026
StartActual
Jan 14, 2026
Primary completionEst.
Mar 2028
CompletionEst.
Jun 4, 2032
Last update
Aug 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07317934
Lead sponsor
Innostellar Biotherapeutics Co.,Ltd
Responsible party
Sponsor
First posted
Jan 5, 2026
Start date
Jan 14, 2026
Primary completion
Mar 2028 (estimated)
Completion
Jun 4, 2032 (estimated)
Last update
Aug 6, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion